Oncoinvent ASA (ONCIN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncoinvent ASA (ONCIN) has a cash flow conversion efficiency ratio of -1.103x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-73.90 Million ≈ $-7.78 Million USD) by net assets (Nkr67.00 Million ≈ $7.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncoinvent ASA - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ONCIN total liabilities for a breakdown of total debt and financial obligations.
Oncoinvent ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncoinvent ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ:ZJYL
|
0.087x |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:200011
|
-0.111x |
|
Alpha Group International plc
LSE:ALPH
|
-0.074x |
|
Hateks Hatay Tekstil Isletmeleri AS
IS:HATEK
|
-0.099x |
|
The Union Mosaic Industry Public Company Limited
BK:UMI
|
0.025x |
|
Hancom MDS Inc
KQ:086960
|
-0.003x |
|
MAG Interactive AB (publ)
ST:MAGI
|
0.031x |
|
INTERSHOP Communications Aktiengesellschaft
XETRA:ISHA
|
0.244x |
Annual Cash Flow Conversion Efficiency for Oncoinvent ASA (2021–2025)
The table below shows the annual cash flow conversion efficiency of Oncoinvent ASA from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see Oncoinvent ASA (ONCIN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr146.32 Million ≈ $15.40 Million |
Nkr-131.19 Million ≈ $-13.80 Million |
-0.897x | +36.62% |
| 2024-12-31 | Nkr108.33 Million ≈ $11.40 Million |
Nkr-153.24 Million ≈ $-16.13 Million |
-1.415x | -30.56% |
| 2023-12-31 | Nkr127.48 Million ≈ $13.41 Million |
Nkr-138.11 Million ≈ $-14.53 Million |
-1.083x | +66.73% |
| 2022-12-31 | Nkr88.50 Million ≈ $9.31 Million |
Nkr-288.23 Million ≈ $-30.33 Million |
-3.257x | -312.75% |
| 2021-12-31 | Nkr384.43 Million ≈ $40.45 Million |
Nkr-303.34 Million ≈ $-31.92 Million |
-0.789x | -- |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.